Prevention of pneumococcal infections: Impact of structured medico-pharmaceutical collaborative management to improve vaccination coverage of at-risk patients (OPTIVACC study): Protocol for a multicenter randomized stepped -wedge study

Background: Streptococcus pneumoniae causes infections especially in patients with immunodeficiency or specific comorbidities. Most could be avoided through pneumococcal vaccination (PV), but PV coverage is only 20 % in France. Many studies assess methods on vaccination coverage improvement, but non...

Full description

Saved in:
Bibliographic Details
Main Authors: Florent Dubois, Emilie Champiot-Bayard, Bogdan Cireașă, Paul Loubet, Jérôme Vallat, Julie Bonnet, Valérie Jacob, Pauline Puyo, Ioana Pînzar, Sarah Théret, Emmanuelle Dubois, Elisabeth Peus, Laurent Giraudon, Clarisse Roux-Marson, Pascale Fabbro-Peray, Géraldine Leguelinel-Blache, Jean-Marie Kinowski
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:Contemporary Clinical Trials Communications
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2451865425000365
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850059876628168704
author Florent Dubois
Emilie Champiot-Bayard
Bogdan Cireașă
Paul Loubet
Jérôme Vallat
Julie Bonnet
Valérie Jacob
Pauline Puyo
Ioana Pînzar
Sarah Théret
Emmanuelle Dubois
Elisabeth Peus
Laurent Giraudon
Clarisse Roux-Marson
Pascale Fabbro-Peray
Géraldine Leguelinel-Blache
Jean-Marie Kinowski
author_facet Florent Dubois
Emilie Champiot-Bayard
Bogdan Cireașă
Paul Loubet
Jérôme Vallat
Julie Bonnet
Valérie Jacob
Pauline Puyo
Ioana Pînzar
Sarah Théret
Emmanuelle Dubois
Elisabeth Peus
Laurent Giraudon
Clarisse Roux-Marson
Pascale Fabbro-Peray
Géraldine Leguelinel-Blache
Jean-Marie Kinowski
author_sort Florent Dubois
collection DOAJ
description Background: Streptococcus pneumoniae causes infections especially in patients with immunodeficiency or specific comorbidities. Most could be avoided through pneumococcal vaccination (PV), but PV coverage is only 20 % in France. Many studies assess methods on vaccination coverage improvement, but none evaluates pharmacist-physician collaboration in hospital on PV coverage of inpatients at-risk of invasive pneumococcal disease (IPD). Methods: This study is a multicentric stepped-wedged randomized trial involving 12 units in 9 French hospitals (3 university and 6 local) during 4 periods of 90 days each. Three clusters will be made, each composed randomly of clinical and surgical units from one university hospital and clinical and surgical units of 2 local hospitals. For each period, one unit will have to include 16 non-vaccinated inpatients at risk of IPD. Patients in the control phase will receive usual care. During the interventional phase, the pharmacist will inform the physician on PV necessity, who will report recommendation and prescribe it at discharge. The pharmacist will perform a consultation and send a discharge letter to the patient's community pharmacist. The primary outcome will assess the impact of intervention on PV coverage after 6 months. Secondary outcomes will evaluate vaccines dispensing, uncompleted protocol rate and intervention process. A subgroup analysis between university and local hospitals and clinical and surgical units, respectively will be made. Discussion: This study will assess the impact of medico-pharmaceutical collaboration in hospital on PV coverage in inpatients at risk of IPD. Hospitalization could be a way to promote vaccination and enhance healthcare system performance. Trial registration: Clinicaltrials.gov, NCT05060146. Registered on September 16th, 2021.
format Article
id doaj-art-bdf39d71e0d14f438b181d5d0a83d51a
institution DOAJ
issn 2451-8654
language English
publishDate 2025-04-01
publisher Elsevier
record_format Article
series Contemporary Clinical Trials Communications
spelling doaj-art-bdf39d71e0d14f438b181d5d0a83d51a2025-08-20T02:50:45ZengElsevierContemporary Clinical Trials Communications2451-86542025-04-014410146210.1016/j.conctc.2025.101462Prevention of pneumococcal infections: Impact of structured medico-pharmaceutical collaborative management to improve vaccination coverage of at-risk patients (OPTIVACC study): Protocol for a multicenter randomized stepped -wedge studyFlorent Dubois0Emilie Champiot-Bayard1Bogdan Cireașă2Paul Loubet3Jérôme Vallat4Julie Bonnet5Valérie Jacob6Pauline Puyo7Ioana Pînzar8Sarah Théret9Emmanuelle Dubois10Elisabeth Peus11Laurent Giraudon12Clarisse Roux-Marson13Pascale Fabbro-Peray14Géraldine Leguelinel-Blache15Jean-Marie Kinowski16Department of Pharmacy, Nimes University Hospital, Univ Montpellier, Nimes, France; Desbrest Institute of Epidemiology and Public Health (IDESP), Univ Montpellier, INSERM, Montpellier, France; Corresponding author. Pharmacy Department, CHU de Nîmes, Prof. Robert Debré square, Nîmes Cedex 9, 30029, France.Department of Pharmacy, Nimes University Hospital, Univ Montpellier, Nimes, FranceDepartment of Pharmacy, Nimes University Hospital, Univ Montpellier, Nimes, FranceDepartment of Infectious and Tropical Diseases, Nimes University Hospital, Univ Montpellier, Nimes, France; VBIC, INSERM U1047, University of Montpellier, Nimes, FranceDepartment of Pharmacy, Montauban Hospital, Montauban, FranceDepartment of Pharmacy, Saint-Gaudens Hospital, Saint-Gaudens, FranceDepartment of Pharmacy, Alès Hospital, Alès, FranceDepartment of Pharmacy, Toulouse Regional University Hospital, Univ Toulouse, Toulouse, FranceDepartment of Pharmacy, Nimes University Hospital, Univ Montpellier, Nimes, FranceDepartment of Pharmacy, Montpellier Regional University Hospital, Univ Montpellier, Montpellier, FranceDepartment of Pharmacy, Bagnols-sur-Ceze Hospital, Bagnols-sur-Ceze, FranceDepartment of Pharmacy, Perpignan Hospital, Perpignan, FranceDepartment of Pharmacy, Sète Hospital, Sète, FranceDepartment of Pharmacy, Nimes University Hospital, Univ Montpellier, Nimes, France; Desbrest Institute of Epidemiology and Public Health (IDESP), Univ Montpellier, INSERM, Montpellier, FranceDesbrest Institute of Epidemiology and Public Health (IDESP), Univ Montpellier, INSERM, Montpellier, France; Department of Biostatistics, Epidemiology, Public Health and Innovation in Methodology, Nimes University Hospital, Nimes, FranceDepartment of Pharmacy, Nimes University Hospital, Univ Montpellier, Nimes, France; Desbrest Institute of Epidemiology and Public Health (IDESP), Univ Montpellier, INSERM, Montpellier, France; Department of Law and Health Economics, Univ Montpellier, Montpellier, FranceDepartment of Pharmacy, Nimes University Hospital, Univ Montpellier, Nimes, France; Desbrest Institute of Epidemiology and Public Health (IDESP), Univ Montpellier, INSERM, Montpellier, FranceBackground: Streptococcus pneumoniae causes infections especially in patients with immunodeficiency or specific comorbidities. Most could be avoided through pneumococcal vaccination (PV), but PV coverage is only 20 % in France. Many studies assess methods on vaccination coverage improvement, but none evaluates pharmacist-physician collaboration in hospital on PV coverage of inpatients at-risk of invasive pneumococcal disease (IPD). Methods: This study is a multicentric stepped-wedged randomized trial involving 12 units in 9 French hospitals (3 university and 6 local) during 4 periods of 90 days each. Three clusters will be made, each composed randomly of clinical and surgical units from one university hospital and clinical and surgical units of 2 local hospitals. For each period, one unit will have to include 16 non-vaccinated inpatients at risk of IPD. Patients in the control phase will receive usual care. During the interventional phase, the pharmacist will inform the physician on PV necessity, who will report recommendation and prescribe it at discharge. The pharmacist will perform a consultation and send a discharge letter to the patient's community pharmacist. The primary outcome will assess the impact of intervention on PV coverage after 6 months. Secondary outcomes will evaluate vaccines dispensing, uncompleted protocol rate and intervention process. A subgroup analysis between university and local hospitals and clinical and surgical units, respectively will be made. Discussion: This study will assess the impact of medico-pharmaceutical collaboration in hospital on PV coverage in inpatients at risk of IPD. Hospitalization could be a way to promote vaccination and enhance healthcare system performance. Trial registration: Clinicaltrials.gov, NCT05060146. Registered on September 16th, 2021.http://www.sciencedirect.com/science/article/pii/S2451865425000365InfectiologyPneumococcal infectionsVaccinationHospital pharmacy
spellingShingle Florent Dubois
Emilie Champiot-Bayard
Bogdan Cireașă
Paul Loubet
Jérôme Vallat
Julie Bonnet
Valérie Jacob
Pauline Puyo
Ioana Pînzar
Sarah Théret
Emmanuelle Dubois
Elisabeth Peus
Laurent Giraudon
Clarisse Roux-Marson
Pascale Fabbro-Peray
Géraldine Leguelinel-Blache
Jean-Marie Kinowski
Prevention of pneumococcal infections: Impact of structured medico-pharmaceutical collaborative management to improve vaccination coverage of at-risk patients (OPTIVACC study): Protocol for a multicenter randomized stepped -wedge study
Contemporary Clinical Trials Communications
Infectiology
Pneumococcal infections
Vaccination
Hospital pharmacy
title Prevention of pneumococcal infections: Impact of structured medico-pharmaceutical collaborative management to improve vaccination coverage of at-risk patients (OPTIVACC study): Protocol for a multicenter randomized stepped -wedge study
title_full Prevention of pneumococcal infections: Impact of structured medico-pharmaceutical collaborative management to improve vaccination coverage of at-risk patients (OPTIVACC study): Protocol for a multicenter randomized stepped -wedge study
title_fullStr Prevention of pneumococcal infections: Impact of structured medico-pharmaceutical collaborative management to improve vaccination coverage of at-risk patients (OPTIVACC study): Protocol for a multicenter randomized stepped -wedge study
title_full_unstemmed Prevention of pneumococcal infections: Impact of structured medico-pharmaceutical collaborative management to improve vaccination coverage of at-risk patients (OPTIVACC study): Protocol for a multicenter randomized stepped -wedge study
title_short Prevention of pneumococcal infections: Impact of structured medico-pharmaceutical collaborative management to improve vaccination coverage of at-risk patients (OPTIVACC study): Protocol for a multicenter randomized stepped -wedge study
title_sort prevention of pneumococcal infections impact of structured medico pharmaceutical collaborative management to improve vaccination coverage of at risk patients optivacc study protocol for a multicenter randomized stepped wedge study
topic Infectiology
Pneumococcal infections
Vaccination
Hospital pharmacy
url http://www.sciencedirect.com/science/article/pii/S2451865425000365
work_keys_str_mv AT florentdubois preventionofpneumococcalinfectionsimpactofstructuredmedicopharmaceuticalcollaborativemanagementtoimprovevaccinationcoverageofatriskpatientsoptivaccstudyprotocolforamulticenterrandomizedsteppedwedgestudy
AT emiliechampiotbayard preventionofpneumococcalinfectionsimpactofstructuredmedicopharmaceuticalcollaborativemanagementtoimprovevaccinationcoverageofatriskpatientsoptivaccstudyprotocolforamulticenterrandomizedsteppedwedgestudy
AT bogdancireasa preventionofpneumococcalinfectionsimpactofstructuredmedicopharmaceuticalcollaborativemanagementtoimprovevaccinationcoverageofatriskpatientsoptivaccstudyprotocolforamulticenterrandomizedsteppedwedgestudy
AT paulloubet preventionofpneumococcalinfectionsimpactofstructuredmedicopharmaceuticalcollaborativemanagementtoimprovevaccinationcoverageofatriskpatientsoptivaccstudyprotocolforamulticenterrandomizedsteppedwedgestudy
AT jeromevallat preventionofpneumococcalinfectionsimpactofstructuredmedicopharmaceuticalcollaborativemanagementtoimprovevaccinationcoverageofatriskpatientsoptivaccstudyprotocolforamulticenterrandomizedsteppedwedgestudy
AT juliebonnet preventionofpneumococcalinfectionsimpactofstructuredmedicopharmaceuticalcollaborativemanagementtoimprovevaccinationcoverageofatriskpatientsoptivaccstudyprotocolforamulticenterrandomizedsteppedwedgestudy
AT valeriejacob preventionofpneumococcalinfectionsimpactofstructuredmedicopharmaceuticalcollaborativemanagementtoimprovevaccinationcoverageofatriskpatientsoptivaccstudyprotocolforamulticenterrandomizedsteppedwedgestudy
AT paulinepuyo preventionofpneumococcalinfectionsimpactofstructuredmedicopharmaceuticalcollaborativemanagementtoimprovevaccinationcoverageofatriskpatientsoptivaccstudyprotocolforamulticenterrandomizedsteppedwedgestudy
AT ioanapinzar preventionofpneumococcalinfectionsimpactofstructuredmedicopharmaceuticalcollaborativemanagementtoimprovevaccinationcoverageofatriskpatientsoptivaccstudyprotocolforamulticenterrandomizedsteppedwedgestudy
AT sarahtheret preventionofpneumococcalinfectionsimpactofstructuredmedicopharmaceuticalcollaborativemanagementtoimprovevaccinationcoverageofatriskpatientsoptivaccstudyprotocolforamulticenterrandomizedsteppedwedgestudy
AT emmanuelledubois preventionofpneumococcalinfectionsimpactofstructuredmedicopharmaceuticalcollaborativemanagementtoimprovevaccinationcoverageofatriskpatientsoptivaccstudyprotocolforamulticenterrandomizedsteppedwedgestudy
AT elisabethpeus preventionofpneumococcalinfectionsimpactofstructuredmedicopharmaceuticalcollaborativemanagementtoimprovevaccinationcoverageofatriskpatientsoptivaccstudyprotocolforamulticenterrandomizedsteppedwedgestudy
AT laurentgiraudon preventionofpneumococcalinfectionsimpactofstructuredmedicopharmaceuticalcollaborativemanagementtoimprovevaccinationcoverageofatriskpatientsoptivaccstudyprotocolforamulticenterrandomizedsteppedwedgestudy
AT clarisserouxmarson preventionofpneumococcalinfectionsimpactofstructuredmedicopharmaceuticalcollaborativemanagementtoimprovevaccinationcoverageofatriskpatientsoptivaccstudyprotocolforamulticenterrandomizedsteppedwedgestudy
AT pascalefabbroperay preventionofpneumococcalinfectionsimpactofstructuredmedicopharmaceuticalcollaborativemanagementtoimprovevaccinationcoverageofatriskpatientsoptivaccstudyprotocolforamulticenterrandomizedsteppedwedgestudy
AT geraldineleguelinelblache preventionofpneumococcalinfectionsimpactofstructuredmedicopharmaceuticalcollaborativemanagementtoimprovevaccinationcoverageofatriskpatientsoptivaccstudyprotocolforamulticenterrandomizedsteppedwedgestudy
AT jeanmariekinowski preventionofpneumococcalinfectionsimpactofstructuredmedicopharmaceuticalcollaborativemanagementtoimprovevaccinationcoverageofatriskpatientsoptivaccstudyprotocolforamulticenterrandomizedsteppedwedgestudy